Skip to main content
Category

Treatments

ResearchTreatments

EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents

*September  2022* In this issue of the Journal of Thoracic Oncology, Piccirillo et al. report the results of the BEVERLY trial, a randomized phase 3 study that reveals the progression-free survival (PFS) benefit of bevacizumab to erlotinib as first-line treatment for Italian patients with metastatic NSCLC with common EGFR mutations. In this large study, after…
laurabbook@gmail.com
September 25, 2022
FDA Food and Drug Admin Logo
ResearchTreatments

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

*August 2022* On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an…
laurabbook@gmail.com
September 25, 2022
lungevity
ResearchTreatments

How to Read Biomarker Test Results

Biomarker testing is used among diagnosed patients with  non-small cell lung cancer (NSCLC) to determine the presence of specific mutations or proteins associated with cancer. It ensures that patients get matched to the right treatment at the right time, based on their biomarker test results. The results can also provide…
laurabbook@gmail.com
September 24, 2022
lungcancer.net
ResearchTreatments

Not all EGFR Mutations Are the Same

By EGFR Resisters Cofounder Ivy Elkins for Lungcancer.net Many of you understand the importance of having biomarker testing when you are diagnosed with lung cancer. This biomarker testing may indicate that you have an EGFR-positive mutation. But what does that mean? What does EGFR mean? First of all, EGFR stands…
laurabbook@gmail.com
September 24, 2022
OncLive
ResearchTreatments

EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC

*July 2022* Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to Marina Garassino, MD. Single-agent osimertinib (Tagrisso) remains the standard of care for…
laurabbook@gmail.com
September 24, 2022
mdpi logo
ResearchTreatments

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

*July 2022* Although it is known that anti-PD1/L1 monotherapy does not render significant benefit in patients with EGFR-mutant lung adenocarcinoma, whether the addition of anti-PD1/L1 therapy to chemotherapy can enhance chemotherapy efficacy for TKI-refractory EGFR-mutant lung adenocarcinoma patients is not clear. To address this question, we retrospectively analyzed a cohort…
laurabbook@gmail.com
September 24, 2022
ResearchTreatments

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

*July 2022* Introduction BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. Methods From October 2016 to May 2020, patients with advanced NSCLC for whom next-generation sequencing detected mutations of both BRAF and…
laurabbook@gmail.com
September 24, 2022